Customer Support: 800-526-4902
 
Home > Legal Library > Advanced Search > Search Results





Practice Area Resource Centers

We currently offer the following Practice Areas: Litigation; Intellectual Property; Real Estate; Corporate Law; Bankruptcy; Business Law; Insurance; Taxation and more...

 






Join Matindale-Hubbell Connected



Hyman, Phelps & McNamara, P.C. Document Search Results (253)

 

View Page: Prev  1  2  3  4  5  6  7  8  9  10  Next  >>
Show: results per page
Sort by:
Sponsored Results

HTMLFDA’s High Risk Pharmacy Inspections and Enforcement Actions: Coming to a Sterile Compounding Pharmacy Near You?
Jeffrey N. Gibbs, Karla L. Palmer; Hyman, Phelps & McNamara, P.C.;
Legal Alert/Article
April 15, 2013, previously published on April 14, 2013
On Thursday, April 11, 2013, FDA published a statement titled, “2013 FDA Pharmacy Inspection Assignment,” addressing the unprecedented recent nationwide wave of aseptic pharmacy inspections. The Agency states that it had taken critical look at its surveillance and enforcement approach...

 

HTMLThe President’s FY 2014 Budget Continues Push to Curb Patent Settlement Agreements, Shorten Biologics Exclusivity; Biologics Exclusivity Faces Opposition in TPP Talks
Kurt R. Karst; Hyman, Phelps & McNamara, P.C.;
Legal Alert/Article
April 15, 2013, previously published on April 11, 2013
Earlier this week, the Obama Administration released the President’s Budget for Fiscal Year 2014. At first blush, FDA appears to have fared rather well, with an additional $821,453,000 in total funding. Most of the increase, however, is due to new user fee revenue, making the increase a bit...

 

HTMLD.C. Circuit Decision May Force FDA and Other Agencies to Expedite Responses to FOIA Requests
Kurt R. Karst; Hyman, Phelps & McNamara, P.C.;
Legal Alert/Article
April 11, 2013, previously published on April 9, 2013
As food and drug attorneys, we rely on a certain level of FDA transparency to understand why FDA did what it did in a particular case, and to discern what that means for future Agency action (or inaction) in another case. One way we get the transparency we need is by submitting Freedom of...

 

HTMLFood Traceability: Recordkeeping Without Regard to Risk?
Ricardo Carvajal; Hyman, Phelps & McNamara, P.C.;
Legal Alert/Article
April 11, 2013, previously published on April 9, 2013
Section 204 of the Food Safety Modernization Act ("FSMA") directed FDA to establish pilot projects “to explore and evaluate methods to rapidly and effectively identify recipients of food to prevent or mitigate a foodborne illness outbreak and to address credible threats of serious...

 

HTMLFederal Court Orders FDA to Approve OTC Emergency Contraception Without Restrictions, Describes Intervention by Secretary Sebelius as “Unprecedented” and “Politically Motivated”
Kurt R. Karst, Etan J. Yeshua; Hyman, Phelps & McNamara, P.C.;
Legal Alert/Article
April 11, 2013, previously published on April 7, 2013
Last Friday, a federal district court judge, in a 59-page decision, ordered FDA to make the emergency contraceptive PLAN B (levonorgestrel) available Over-the-Counter (“OTC”) and without age restrictions. In doing so, Judge Edward R. Korman of the U.S. District Court for the Eastern...

 

HTMLAre Your “Natural” Food and Supplement Ingredients Really Natural? The National Organic Program Issues Draft Guidance Concerning Definition of Natural vs. Synthetic
Riëtte van Laack; Hyman, Phelps & McNamara, P.C.;
Legal Alert/Article
April 6, 2013, previously published on April 5, 2013
Under the Organic Food Production Act (“OFPA”), the National Organic Program (“NOP”) of the USDA is authorized to establish the National List of Allowed and Prohibited Substances (“National List”). This National List contains each synthetic substance that is...

 

HTMLDEA Endorses Citizen Petition To Limit Approved Uses and Impose Maximum Day and Quantity Limits on Controlled Release Oxycodone-Hydrochloride
Delia A. Stubbs; Hyman, Phelps & McNamara, P.C.;
Legal Alert/Article
April 4, 2013, previously published on April 3, 2013
As previously reported, Congress recently introduced the Stop Oxy Abuse Act that would restrict the labeled indications for use of any controlled release drug containing Oxycodone-Hydrochloride (HCl) to “severe-only” versus current labeling of “moderate-to- severe” pain. The...

 

HTMLDiscord Among Accord and Acorda Over AMPYRA Biostudy Sample Leads to Restricted Distribution Antitrust Lawsuit
Kurt R. Karst; Hyman, Phelps & McNamara, P.C.;
Legal Alert/Article
April 3, 2013, previously published on April 2, 2013
A recent Complaint filed in the U.S. District Court for the Southern District of Florida by Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd. (collectively, “Accord Healthcare”) against Acorda Therapeutics Inc. (“Acorda”) and H.D. Smith Wholesale Drug Co. (“H.D....

 

HTMLFSMA Preventive Controls and OMB: No Cloak or Dagger
Ricardo Carvajal; Hyman, Phelps & McNamara, P.C.;
Legal Alert/Article
April 3, 2013, previously published on April 2, 2013
When FDA published its proposed rule on preventive controls as authorized by FSMA, we noted that FDA requested comment on a number of important issues that were not addressed in the text of the regulation itself, namely product testing, environmental monitoring, and supplier approval and...

 

HTMLAdministrative Law Trumps the “Immutable Laws of Science,” Says the DC Circuit in Challenge Over Generic Derma-Smoothe Approvals; Hill Appeals and Denial Quickly Follows
Kurt R. Karst; Hyman, Phelps & McNamara, P.C.;
Legal Alert/Article
April 2, 2013, previously published on March 28, 2013
A recent per curiam decision from the U.S. Court of Appeals for the District of Columbia Circuit may be the last word in litigation Hill Dermaceuticals, Inc. (“Hill”) initiated in November 2011 against FDA, as Hill filed a petition for rehearing last week that was denied earlier this...

 


View Page: Prev  1  2  3  4  5  6  7  8  9  10  Next  >>